Translational Psychiatry, an esteemed journal published by SpringerNature, is at the forefront of research in the fields of biological psychiatry, neuroscience, and mental health. With an impressive Q1 category ranking in Biological Psychiatry, Cellular and Molecular Neuroscience, and Psychiatry and Mental Health, the journal fosters high-quality scholarly work that informs clinical practices and guides future research directions. Since its inception in 2011, Translational Psychiatry has embraced the Open Access model, ensuring that groundbreaking findings are easily accessible to all, promoting collaboration and innovation within the global scientific community. With a solid ranking in Scopus—particularly at #33 out of 567 in Psychiatry and Mental Health and #6 out of 51 in Biological Psychiatry—this journal plays a critical role in advancing our understanding of mental health disorders, bridging the gap between bench science and clinical application. As it continues evolving through its converged years from 2011 to 2024, Translational Psychiatry remains an essential resource for researchers, healthcare professionals, and students dedicated to improving mental health outcomes.

Frontiers in Psychiatry is a leading journal dedicated to advancing research within the field of psychiatry and mental health. Published by FRONTIERS MEDIA SA, the journal has established a commendable reputation since its inception, reflected in its Q1 status in the 2023 Psychiatry and Mental Health category and a robust ranking of 142 out of 567 in the Scopus database. With an open access model initiated in 2009, Frontiers in Psychiatry aims to disseminate high-quality research to a global audience, fostering collaboration and innovation among researchers, clinicians, and students alike. The journal covers a broad spectrum of topics, including neurobiology, psychosocial factors, treatments, and public health implications of mental disorders, ensuring comprehensive representation of contemporary psychiatric science. Located in Lausanne, Switzerland, and running until 2024, the journal not only emphasizes the importance of mental health research but also encourages interdisciplinary discourse, making it an essential resource for anyone invested in the well-being of individuals and communities alike.

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Trends in Psychiatry and Psychotherapy, published by ASSOC PSIQUIATRIA RIO GRANDE SUL, is a leading open-access journal dedicated to advancing the fields of psychiatry and mental health. Since its inception in 2011, this Brazilian journal has committed itself to disseminating high-quality research and innovative clinical practices, providing a platform for both established researchers and emerging voices in the field. With a notable impact factor and ranking within the Q2 quartile for both psychiatry and miscellaneous medicine categories in 2023, this journal is recognized for its significant contribution to the academic community. It serves as a vital resource for researchers, professionals, and students alike, facilitating knowledge exchange and fostering collaboration across disciplines. The open-access model ensures that cutting-edge findings are accessible to a global audience, enhancing the discourse surrounding mental health and psychiatric care. For more information and to explore current publications, please visit the journal's website.

Welcome to the Journal of Behavior Therapy and Experimental Psychiatry, a distinguished publication in the field of psychological research, recognized for its commitment to advancing knowledge in behavior therapy and experimental psychiatry. Published by Pergamon-Elsevier Science Ltd in the United Kingdom, this journal plays a crucial role in disseminating innovative findings and theoretical advancements since its inception in 1970. With an impressive array of impact factors, this journal proudly holds a Q1 ranking in Arts and Humanities (miscellaneous) and Q2 rankings across Clinical Psychology, Experimental and Cognitive Psychology, and Psychiatry and Mental Health categories in 2023. The journal provides a platform for both established researchers and emerging scholars to share insights that enhance practice and inform policy in mental health. Although not an Open Access journal, it ensures broad accessibility to its content through institutional subscriptions and affiliations. By focusing on high-quality, rigorous research, the Journal of Behavior Therapy and Experimental Psychiatry continues to shape the understanding of behavioral interventions and their psychological implications, making it an indispensable resource for professionals and students alike.

PSYCHIATRY RESEARCH is a leading journal published by Elsevier Ireland Ltd, dedicated to advancing the field of psychiatry and mental health through the dissemination of rigorous research. With an impressive impact factor and categorized in the top quartile (Q1) of both Biological Psychiatry and Psychiatry and Mental Health in 2023, this journal ranks 14th in the field of Medicine _ Psychiatry and Mental Health out of 567 journals, and 4th in Neuroscience _ Biological Psychiatry out of 51, showcasing its influence and quality. Since its inception in 1979, PSYCHIATRY RESEARCH has provided a platform for innovative studies, clinical trials, and comprehensive reviews aimed at understanding the complexities of mental health disorders. Although it operates under a traditional access model, the journal remains committed to making vital research available to the academic community, ensuring that both seasoned professionals and budding researchers have access to groundbreaking findings. Positioned as a hub for psychiatric research, it caters to a diverse audience including clinicians, psychologists, and students, empowering them to contribute to the evolving landscape of mental health care.

PSYCHIATRIC GENETICS, published by LIPPINCOTT WILLIAMS & WILKINS, is a pivotal journal dedicated to the interdisciplinary study of genetic factors in psychiatric disorders, bridging the fields of genetics, psychiatry, and neuroscience. With a commitment to advancing research from its inception in 1990 and continuing through 2024, the journal provides a platform for innovative studies and findings that explore the genetic underpinnings of mental health. Although not currently an Open Access publication, it reaches a wide audience concerned with the complex interplay between genetics and psychiatric conditions, contributing to its Q3 and Q2 quartile rankings across multiple relevant categories in 2023. The importance of this journal cannot be understated; it serves as a crucial resource for researchers, clinicians, and students eager to uncover insights that could lead to more effective interventions and treatments in the realm of mental health.

European Archives of Psychiatry and Clinical Neuroscience is a prominent peer-reviewed journal published by Springer Heidelberg, focusing on the interdisciplinary aspects of psychiatry and clinical neuroscience. With an ISSN of 0940-1334 and an E-ISSN of 1433-8491, this journal provides a rigorous platform for innovative research spanning biological psychiatry, pharmacology, and various aspects of mental health. The journal boasts a distinguished impact factor that places it in the Q2 category for Biological Psychiatry and Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health as of 2023, reflecting its significant contribution to the field. Additionally, its Scopus rankings highlight its esteemed position among the top journals, particularly in Medicine and Neuroscience disciplines. Readers can access a wealth of valuable research articles, case studies, and reviews, crucial for advancing understanding and treatment within these vital fields. Initially converged in 1990, the journal continues to evolve and support scholarly dialogue until 2024 and beyond, making it an essential resource for researchers, clinicians, and students alike.

ACTA NEUROPSYCHIATRICA is a distinguished journal published by Cambridge University Press, covering essential research across the fields of psychiatry and neuroscience. Since its inception in 1989, it has become a pivotal resource for researchers and clinicians, providing a platform for the latest advancements and insights in biological psychiatry. With an impressive Scopus rank of #66 out of 567 in the Psychiatry and Mental Health category, and #10 out of 51 in Biological Psychiatry, the journal is recognized for its significant contributions to the field, boasting an 88th percentile ranking in overall impact. Although it operates under a traditional access model, the journal remains committed to disseminating high-quality research that addresses critical issues in mental health. Whether you are a professional seeking the latest findings or a student aiming to deepen your knowledge, ACTA NEUROPSYCHIATRICA is an indispensable resource for cutting-edge developments that shape our understanding of the human mind.